India-US Trade Deal Gives Major Boost to MedTech and Pharma Sectors
NEW DELHI (TheTrendingPeople): Industry experts on Tuesday said the India-US trade agreement, which reduces tariffs on Indian exports to 18 per cent from 50 per cent, will significantly benefit the country’s medical devices and pharmaceutical sectors.
The United States remains India’s largest export destination, accounting for nearly 20 per cent of total exports. The sharp tariff reduction is expected to improve competitiveness and expand market access for Indian healthcare manufacturers.
The Association of Indian Medical Devices (AiMeD) welcomed the move, calling it a major opportunity for domestic companies. Forum Coordinator Rajiv Nath said the cut would lower export costs and unlock new growth avenues, especially under the China+1 supply chain strategy.
He added that Indian products will now enjoy an advantage over Chinese competitors, who continue to face higher Section 301 tariffs.
The pharmaceutical sector also reacted positively. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) said the deal would support companies with strong US exposure.
Chairman Namit Joshi noted that the US contributes 30–40 per cent of sector revenue and improved access will strengthen exports of generics and biosimilars.
Our Final Thoughts
The tariff cut marks a key step in strengthening India’s healthcare exports. With better access and lower costs, Indian MedTech and pharma firms are well-positioned for long-term global growth.
